New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® Read more about New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® SIGA Reports Financial Results for Three Months Ended March 31, 2022 Read more about SIGA Reports Financial Results for Three Months Ended March 31, 2022 SIGA Declares Special Dividend of $0.45 Per Share Read more about SIGA Declares Special Dividend of $0.45 Per Share SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 Read more about SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials Read more about SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech Read more about SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 Read more about SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX® Read more about New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
SIGA Reports Financial Results for Three Months Ended March 31, 2022 Read more about SIGA Reports Financial Results for Three Months Ended March 31, 2022
SIGA Declares Special Dividend of $0.45 Per Share Read more about SIGA Declares Special Dividend of $0.45 Per Share
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021 Read more about SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials Read more about SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results Read more about SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech Read more about SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022 Read more about SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat Read more about SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat